Slone Partners Places John Leite as Chief Business Officer at InterVenn Biosciences
SOUTH RIDING, Va., Dec. 3, 2020 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of John Leite as Chief Business Officer at InterVenn Biosciences .
SOUTH RIDING, Va., Dec. 3, 2020 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of John Leite as Chief Business Officer at InterVenn Biosciences. In his new role, Leite will direct all business operations for the company as part of its global leadership team.
Over the past six years, Leite served as Vice President of Oncology, Market Development & Product Marketing for the oncology business unit at Illumina. Prior to joining Illumina, Leite was Vice President of Commercial Strategy and Market Access for Genoptix Inc., where, from 2008 until 2014, he drove several functions including marketing and business development, building the portfolio of oncology diagnostic services. Leite began his career as a scientist for Invitrogen (now Thermo Fisher Scientific), before transitioning to the business team as a marketer overseeing product management of the proteomics portfolio.
"John Leite is an experienced and highly accomplished business development and marketing specialist in the biotechnology and diagnostics sectors," said Slone Partners President Tara Kochis-Stach. "He brings a keen strategic sensibility and an extremely successful track record to the InterVenn executive team."
"We are thrilled to bring John on board at a very exciting time for our company," said Aldo Carrascoso, Chief Executive Officer at InterVenn. "He and the rest of our global leadership team are poised to move us forward as we continue to make tremendous progress in the diagnosis and treatment of various diseases through the use of glycoproteomics."
Leite earned his PhD in Biochemistry at the University of Pittsburgh School of Medicine. He also served his post-doc in Neuroscience at the California Institute of Technology.
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.
ABOUT INTERVENN BIOSCIENCES
Based in South San Francisco, InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information, please visit the company's website at https://intervenn.bio/.
Media Contact
Doug Gavel, Doug Gavel Communications, (617) 429-4417, [email protected]
SOURCE Slone Partners
